Literature DB >> 18353724

The NKG2D receptor: sensing stressed cells.

Carlos López-Larrea1, Beatriz Suárez-Alvarez, Alejandro López-Soto, Antonio López-Vázquez, Segundo Gonzalez.   

Abstract

The activating killer cell lectin-like receptor NKG2D plays a key role in the natural killer (NK) cell-mediated lysis of tumours and infected cells. Unlike other receptors, the ligands recognised by NKG2D are 'induced-self' ligands on stressed cells. This system requires precise regulation because inappropriate expression of NKG2D ligands might compromise NK cell activation. For therapeutic purposes it is essential to understand the mechanisms that regulate the expression and function of the NKG2D system. This review focuses on the importance of the signalling pathways involved in the regulation of the NKG2D receptor and its ligand expression in arming the immune response against infected or tumour cells and for the identification of new molecular targets and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353724     DOI: 10.1016/j.molmed.2008.02.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  41 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  EphA2 targeting peptide tethered bioreducible poly(cystamine bisacrylamide-diamino hexane) for the delivery of therapeutic pCMV-RAE-1γ to pancreatic islets.

Authors:  Katherine S Blevins; Ji Hoon Jeong; Mei Ou; Jonathan H Brumbach; Sung Wan Kim
Journal:  J Control Release       Date:  2011-10-28       Impact factor: 9.776

3.  Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.

Authors:  Weijuan Gong; Weiming Xiao; Li Qian; Chunxiang Gong; Maozhi Hu; Xianyuan Pan; Mingchun Ji
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

4.  Conceptual aspects of self and nonself discrimination.

Authors:  Segundo Gonzalez; Ana Pilar González-Rodríguez; Beatriz Suárez-Álvarez; Alejandro López-Soto; Leticia Huergo-Zapico; Carlos Lopez-Larrea
Journal:  Self Nonself       Date:  2011-01-01

Review 5.  Targeted immune therapy of ovarian cancer.

Authors:  Keith L Knutson; Lavakumar Karyampudi; Purushottam Lamichhane; Claudia Preston
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

Review 6.  Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase.

Authors:  Bizhan Romani; Eric A Cohen
Journal:  Curr Opin Virol       Date:  2012-10-10       Impact factor: 7.090

Review 7.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

8.  Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells.

Authors:  Ulrich Langenkamp; Uwe Siegler; Simon Jörger; Stefan Diermayr; Alois Gratwohl; Christian P Kalberer; Aleksandra Wodnar-Filipowicz
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 9.  Immunogenetics of the NKG2D ligand gene family.

Authors:  Masanori Kasahara; Shigeru Yoshida
Journal:  Immunogenetics       Date:  2012-07-29       Impact factor: 2.846

10.  Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells.

Authors:  Beatriz Suárez-Alvarez; Ramón M Rodriguez; Vincenzo Calvanese; Miguel A Blanco-Gelaz; Steve T Suhr; Francisco Ortega; Jesus Otero; Jose B Cibelli; Harry Moore; Mario F Fraga; Carlos López-Larrea
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.